Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Non Operating Income for 3 consecutive years, with -$13.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 812161.31% year-over-year to -$13.9 million; the trailing twelve-month figure through Jun 2026 stood at -$7.9 million (down 7476.69% YoY), and the FY2025 full-year result was $5.9 million, up 5245.07% from the prior year.
• Non Operating Income eased to -$13.9 million in Q2 2026 per APUS's latest filing, from $5.9 million in the prior quarter.
• Across five years, Non Operating Income topped out at $5.9 million in Q4 2025 and bottomed at -$13.9 million in Q2 2026.
• Historically, Non Operating Income has averaged -$899759.9 across 3 years, with a median of -$24747.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Non Operating Income soared 16437.48% in 2025, then sank 812161.31% in 2026.
• Over 3 years, Non Operating Income stood at -$36020.0 in 2024, then jumped by 16437.48% to $5.9 million in 2025, then sank by 336.11% to -$13.9 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$13.9 million, $5.9 million, and $62984.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.